ABSTRACT Despite considerable pathological diversity, pediatric sarcomas lack molecularly targeted treatments, demanding deeper pathobiological insights and innovative therapeutic strategies. Here, we demonstrate that overexpressed MDM2 functions as an important pathogenic driver in these malignancies, rewiring oncogenic programs through both p53‐independent chromatin occupancy to regulate active transcription and conventional proteasome‐mediated p53 degradation leading to pathway suppression. T